- Lantheus Holdings (LNTH, Financial) completes acquisition of Life Molecular Imaging Ltd.
- Neuraceq®, an FDA-approved F-18 PET imaging agent, enhances Alzheimer's diagnostics.
- Dr. Ludger Dinkelborg appointed Head of R&D at Lantheus, effective August 1, 2025.
Lantheus Holdings, Inc. (LNTH) has successfully finalized its acquisition of Life Molecular Imaging Ltd., a subsidiary of Life Healthcare Group Holdings Ltd. This strategic acquisition bolsters Lantheus's position in the Alzheimer's diagnostic market by acquiring Neuraceq®, a globally approved F-18 PET imaging agent used for detecting beta-amyloid plaques in Alzheimer's disease evaluation. This move is expected to significantly enhance Lantheus's commercial infrastructure, R&D capabilities, and international presence.
The acquisition also marks a significant leadership enhancement as Dr. Ludger Dinkelborg, the former CEO of Life Molecular Imaging, will assume the role of Head of Research and Development at Lantheus starting August 1, 2025. Dr. Dinkelborg will be instrumental in overseeing Clinical Development, Regulatory Affairs, Clinical Operations, Program Management, and AI/Biomarkers Solutions. His appointment is seen as a commitment to advancing Lantheus's innovation pipeline and improving patient care outcomes.
This transaction aligns with Lantheus's broader strategy of enhancing its footprint in the precision medicine industry, particularly in neurodegenerative disease diagnostics. The demand for companion diagnostics like Neuraceq® is anticipated to grow, given the industry trend towards early and precise diagnosis of Alzheimer's disease.
